Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC reduced its stake in Ascendis Pharma A/S (NASDAQ:ASNDFree Report) by 6.6% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 151,656 shares of the biotechnology company’s stock after selling 10,756 shares during the period. Ascendis Pharma A/S accounts for about 1.2% of Rice Hall James & Associates LLC’s investment portfolio, making the stock its 19th biggest holding. Rice Hall James & Associates LLC owned about 0.26% of Ascendis Pharma A/S worth $20,683,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently made changes to their positions in the stock. Private Ocean LLC acquired a new position in Ascendis Pharma A/S during the 1st quarter valued at about $36,000. Quadrant Capital Group LLC grew its holdings in Ascendis Pharma A/S by 90.4% in the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after buying an additional 151 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in Ascendis Pharma A/S by 37.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock worth $42,000 after buying an additional 91 shares in the last quarter. GAMMA Investing LLC increased its position in Ascendis Pharma A/S by 52.0% in the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 102 shares during the period. Finally, Barometer Capital Management Inc. bought a new stake in Ascendis Pharma A/S during the 4th quarter valued at $126,000.

Ascendis Pharma A/S Trading Down 1.8 %

Shares of Ascendis Pharma A/S stock opened at $114.76 on Wednesday. Ascendis Pharma A/S has a 1 year low of $85.29 and a 1 year high of $161.00. The company has a market cap of $6.68 billion, a P/E ratio of -11.94 and a beta of 0.63. The stock has a 50-day moving average price of $133.61 and a 200 day moving average price of $137.33.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ASND shares. TD Cowen decreased their price target on Ascendis Pharma A/S from $175.00 to $157.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. Jefferies Financial Group increased their target price on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a research report on Tuesday, August 13th. Evercore ISI upgraded shares of Ascendis Pharma A/S to a “strong-buy” rating in a research report on Monday, August 26th. Morgan Stanley increased their price objective on shares of Ascendis Pharma A/S from $116.00 to $140.00 and gave the company an “equal weight” rating in a report on Thursday, May 16th. Finally, Bank of America boosted their target price on Ascendis Pharma A/S from $165.00 to $175.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. Two investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Ascendis Pharma A/S currently has an average rating of “Moderate Buy” and a consensus target price of $187.08.

Get Our Latest Analysis on Ascendis Pharma A/S

Ascendis Pharma A/S Company Profile

(Free Report)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

Featured Articles

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASNDFree Report).

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.